Sanara MedTech Inc. SMTI
- Market cap
- $322.5M
- P/E
- 0.0×
Follow SMTI
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.00 | 4.00 | 2.00 | 2.00 | 7.04 | 21.30 | 17.41 | 26.06 | 26.00 | 18.90 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 9.00 | 10.00 | 75.00 | 16.37 | 53.85 | 49.70 | 46.85 | 50.18 | 43.25 | 38.68 |
High Price
|
|||
| 12 | 18 | 21 | 40 | 41 | 68 | 103 | 108 | 141 | 108 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Revenue/Emp
|
|||
| 6 | 6 | 9 | 12 | 16 | 24 | 46 | 65 | 87 | 103 |
Revenue
|
|||
| 82.87% | 87.22% | 90.29% | 89.72% | 89.63% | 90.43% | 86.12% | 87.92% | 90.61% | 92.71% |
Gross Margin
|
|||
| 0 | 0 | 0 | (3) | (4) | (8) | (14) | (4) | (2) | 0 |
EBT
|
|||
| (7.55%) | 5.25% | 2.00% | (24.10%) | (28.52%) | (33.11%) | (30.40%) | (6.83%) | (2.24%) | (0.38%) |
EBT Margin
|
|||
| 0 | 0 | 0 | (3) | (4) | (8) | (8) | (4) | (10) | (38) |
Net Income
|
|||
| 0 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 5 | 4 |
Depreciation
|
|||
| 5.07 | 5.66 | 4.24 | 5.52 | 2.72 | 3.29 | 5.80 | 7.85 | 10.22 | 11.96 |
Revenue/Sh
|
|||
| (0.38) | 0.00 | (0.25) | (1.32) | (0.76) | (1.08) | (1.00) | (0.52) | (1.14) | (4.36) |
Earnings/Sh
|
|||
| 0.38 | (0.13) | 0.25 | (1.02) | (0.70) | (0.66) | (0.70) | (0.39) | 0.00 | 0.79 |
Cash Flow/Sh
|
|||
| 0.00 | (0.08) | (0.01) | (0.80) | (0.29) | (0.10) | (0.09) | (0.03) | (0.03) | (0.53) |
Capex/Sh
|
|||
| 0.37 | (0.20) | 0.24 | (1.82) | (0.99) | (0.76) | (0.80) | (0.42) | (0.03) | 0.25 |
Free CF/Sh
|
|||
| (0.39) | 0.09 | 0.28 | 3.00 | 1.02 | 4.11 | 5.28 | 5.39 | 4.59 | 0.69 |
Book Value/Sh
|
|||
| 1 | 1 | 2 | 2 | 6 | 7 | 8 | 8 | 8 | 9 |
Shares
|
|||
| 0.00 | 26.93 | 37.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 1.08 | 1.06 | 0.71 | 2.92 | 18.36 | 8.99 | 6.99 | 5.22 | 3.25 | 1.95 |
PS Ratio
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 49.00 | 7.20 | 7.68 | 7.60 | 7.24 | 33.96 |
PB Ratio
|
|||
| 1.18 | 1.18 | 0.86 | 2.49 | 18.36 | 8.23 | 6.81 | 5.29 | 3.43 | 2.25 |
EV/Sales
|
|||
| (1.09) | (43.62) | 15.39 | (7.50) | (50.40) | (35.71) | (49.54) | (83.57) | (348.62) | 106.57 |
EV/FCF
|
|||
| 0 | 0 | 1 | (2) | (4) | (5) | (6) | (3) | 0 | 7 |
Op' Cash Flow
|
|||
| 0 | 0 | 0 | (2) | (2) | (1) | (1) | 0 | 0 | (5) |
Capex
|
|||
| 0 | 0 | 0 | (4) | (6) | (6) | (6) | (4) | 0 | 2 |
FCF
|
|||
| 1 | 0 | 1 | 6 | 1 | 19 | 8 | 5 | 18 | 15 |
Working Cap'
|
|||
| 2 | 1 | — | 2 | 0 | 0 | 1 | 10 | 31 | 46 |
Total Debt
|
|||
| 1 | 1 | 0 | (5) | 0 | (18) | (8) | 5 | 15 | 29 |
Net Debt
|
|||
| 0 | 0 | 1 | 6 | 6 | 30 | 42 | 45 | 39 | 6 |
Sh' Equity
|
|||
| (38.03%) | 8.76% | 2.25% | (43.88%) | (41.60%) | (34.28%) | (16.29%) | (6.38%) | (11.93%) | (46.65%) |
ROA
|
|||
| (47.04%) | 8.97% | 32.30% | (122.50%) | (53.64%) | (38.66%) | (23.30%) | (5.36%) | 1.46% | 12.92% |
ROIC
|
|||
| 40.41% | (18.92%) | (0.77%) | 35.72% | (1,007.96%) | (44.02%) | (22.09%) | (9.97%) | (23.15%) | (167.53%) |
ROE
|
|||
Sanara MedTech Inc. peers in Medical Instruments & Supplies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| EMBC Embecta Corp. | $316.2M | 4.0× | Compare |
| OSUR OraSure Technologies, Inc. | $271.1M | 0.0× | Compare |
| UTMD Utah Medical Products, Inc. | $238.0M | 22.7× | Compare |
| PDEX Pro-Dex, Inc. | $233.9M | 17.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ANGO AngioDynamics, Inc. | $631.6M | 0.0× | Compare |
| ZJYL Jin Medical International Ltd. | $159.2M | — | Compare |
| KRMD KORU Medical Systems, Inc. | $151.0M | 0.0× | Compare |
| AVR Anteris Technologies Global Corp. | $745.6M | 0.0× | Compare |
Sanara MedTech Inc. (SMTI) key facts
- Sanara MedTech Inc. (SMTI) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
- Sanara MedTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $103.1 million, up 19.0% from fiscal 2024.
- As of September 25, 2026, SMTI traded at $35.06, a market capitalization of $322.5 million.
- Return on equity was −167.5% and debt-to-equity 5.86.
Sanara MedTech Inc. (SMTI) Latest News
11 Aug
Sanara MedTech Inc. topped Q2 earnings estimates. Beating Q2 earnings estimates lifts Sanara MedTech Inc. stock and investor sentiment without altering long-term trajectory.
Sanara MedTech Inc. reported unaudited second quarter 2026 financial results. Quarterly earnings releases routinely move stock prices through updated performance data.
29 Jul
MIMEDX plans to acquire Sanara MedTech Inc. (SMTI). Acquisition by MIMEDX will transform Sanara MedTech's independent operations and long-term market position.
22 Jun
Analysts raised Sanara MedTech (SMTI) fair value citing expected wound care growth. Analyst fair value bump backed by wound care growth prospects moderately influences SMTI investor sentiment and near-term performance.
2 Jun
Sanara MedTech Inc. (SMTI) released its Q1 2026 earnings transcript covering financial results, operational updates, and forward outlook. Quarterly earnings release supplies financial metrics and guidance that can moderately shift near-term investor sentiment and valuation.
13 May
Sanara MedTech Inc. summarized Q1 2026 earnings call, reporting financial results, operational updates, and forward guidance. Q1 earnings summaries signal major financial shifts influencing SMTI's trajectory and investor sentiment.
12 May
Sanara MedTech Inc. (SMTI) reported strong revenue growth and strategic initiatives in Q1 2026 earnings call highlights. Strong revenue growth and strategic initiatives indicate significant positive impact on SMTI's financial performance and market trajectory.
11 May
Sanara MedTech Inc. (SMTI) reported unaudited financial results for the first quarter of 2026. Quarterly earnings reports often drive significant shifts in stock price and investor perceptions of future performance.
5 May
Sanara MedTech Inc. (SMTI) reframes its growth story around a steady US$34 target, highlighting consistent expansion and strategic positioning. Reframing the growth narrative around a US$34 target constitutes a major strategic communication likely to significantly enhance investor sentiment and stock trajectory.
4 May
Sanara MedTech Inc. (SMTI) released its Q4 2025 earnings call transcript detailing financial results, operational updates, and forward-looking guidance. Q4 earnings transcript discloses key financial metrics, strategic initiatives, and guidance that significantly shape investor expectations and market performance.
23 Apr
Sanara MedTech Inc. (SMTI) emerges as a compelling risk-reward investment opportunity due to its strong growth potential, innovative products, and undervalued stock amid expanding market opportunities in wound care and surgical solutions. SMTI's highlighted growth drivers and undervaluation signal moderate positive influence on financial performance and investor sentiment.
20 Apr
Sanara MedTech (SMTI) investment narrative shifts as analysts introduce new price targets and revised growth assumptions, signaling evolving expectations for the company's future performance. New analyst targets and growth assumptions represent a significant strategic shift likely to alter SMTI's market trajectory and investor sentiment.
25 Mar
Sanara MedTech Inc. (SMTI) released Q4 2025 earnings call summary highlighting financial results, operational updates, and future outlook. Q4 earnings call summary discloses financial performance and strategic guidance that significantly shape investor expectations and stock trajectory.
24 Mar
Sanara MedTech Inc. (SMTI) reported record Q4 2025 revenue alongside strategic growth initiatives in earnings call highlights. Record revenue and strategic growth signal major positive shifts in financial trajectory and investor outlook.
Sanara MedTech Inc. (SMTI) Q4 earnings call highlights key financial results, revenue growth, operational updates, and forward guidance for the medtech firm. Q4 earnings highlights reveal financial performance and strategic outlook significantly shaping investor sentiment and stock trajectory.
Sanara MedTech Inc. reported unaudited fourth quarter and full-year 2025 financial results while reaffirming full-year 2026 financial guidance. Financial results disclosure and reaffirmed 2026 guidance significantly shape investor sentiment and stock trajectory.
Sanara MedTech Inc. (SMTI) Q4 earnings missed analyst estimates. Q4 earnings miss affects key financial performance and investor sentiment with moderate overall influence.
11 Mar
Sanara MedTech Inc. announces publication of peer-reviewed study evaluating economic and clinical value of CellerateRX® Surgical Powder in managing spine surgery wounds. Peer-reviewed study validating CellerateRX Surgical Powder's economic and clinical benefits in spine surgery strengthens SMTI's product credibility and competitive positioning.
23 Jan
Sanara MedTech Inc. reported its unaudited preliminary financial results for the fourth quarter and full year of 2025, highlighting significant growth and operational achievements. The company also introduced its financial guidance for the full year 2026, indicating expectations for continued progress and strategic initiatives aimed at enhancing market presence and product offerings. The introduction of financial guidance for 2026 and the reported growth suggest significant strategic moves that could impact the company's future performance.
7 Jan
Sanara MedTech Inc. has secured an Innovative Technology Contract from Vizient for its BIASURGE® Advanced Surgical Solution. This contract aims to enhance the availability of advanced surgical solutions in healthcare settings, potentially improving patient outcomes and operational efficiencies. The partnership with Vizient is expected to facilitate broader access to Sanara's innovative products within the healthcare market. The contract with Vizient is a significant strategic move that could enhance market access and influence future financial performance.
6 Jan
Sanara MedTech Inc. (SMTI) has been upgraded to a Strong Buy rating, reflecting positive sentiment around the company's growth potential and market position. Analysts highlight recent developments and strategic initiatives that could enhance financial performance and investor confidence. The upgrade suggests a favorable outlook for SMTI, indicating that it may outperform market expectations in the near future. The upgrade to Strong Buy indicates significant positive sentiment and potential for improved market performance.
10 Dec
Sanara MedTech Inc. and Biomimetic Innovations have provided an update on their OsStic™ product, which is designed for bone regeneration. The collaboration aims to enhance the product's effectiveness and market reach, with ongoing clinical evaluations and positive feedback from healthcare professionals. The companies are focused on advancing the technology to improve patient outcomes in orthopedic and dental applications. The update on OsStic™ indicates significant advancements in product development that could enhance market positioning and investor sentiment.
15 Nov
Sanara MedTech Inc. has decided to discontinue its THP division and is refocusing its strategy following the reporting of quarterly losses. The company aims to streamline operations and concentrate on its core products to improve financial performance and market positioning. Discontinuing the THP division and refocusing strategy may moderately influence financial performance and competitive positioning.
13 Nov
Sanara MedTech Inc. (SMTI) reported a quarterly earnings beat, reflecting a strategic shift in its operations. The company is focusing on expanding its product offerings and enhancing market presence, which may positively influence its valuation. Analysts are assessing the implications of these changes on future performance and investor sentiment. The strategic shift and earnings beat are likely to significantly impact the company's future trajectory and market performance.
12 Nov
Sanara MedTech Inc. (SMTI) reported strong revenue growth in its Q3 2025 earnings call, highlighting strategic initiatives that contributed to its performance. The company emphasized advancements in product offerings and market expansion efforts, which are expected to enhance its competitive positioning. Management expressed optimism about future growth prospects and ongoing investments in innovation. Strong revenue growth and strategic initiatives indicate significant potential for future performance and market positioning.
Sanara MedTech Inc. (SMTI) reported its third-quarter earnings, surpassing analysts' expectations. The company demonstrated strong financial performance, driven by increased demand for its innovative medical products. This positive outcome reflects the effectiveness of its strategic initiatives and positions SMTI favorably in the competitive healthcare market. Surpassing earnings estimates indicates significant operational strength and potential for future growth.
Sanara MedTech Inc. reported its unaudited financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and operational performance. The company continues to focus on expanding its product offerings and market presence, aiming to enhance shareholder value. Management expressed optimism about future prospects and ongoing initiatives to drive innovation and efficiency within the organization. Revenue growth and operational performance may moderately influence financial performance and market sentiment.
11 Nov
Sanara MedTech Inc. has announced a strategic realignment to concentrate on its surgical business. This decision aims to enhance operational efficiency and drive growth in its core surgical product offerings. The company believes that focusing on this segment will better position it in the competitive landscape and improve overall performance. The strategic realignment to focus on the surgical business is expected to significantly impact the company's future performance and market positioning.
29 Oct
Sanara MedTech Inc. (SMTI) is highlighted among three growth companies with significant insider ownership, reaching up to 31%. This insider ownership is often viewed as a positive indicator of management's confidence in the company's future prospects. The article emphasizes the potential benefits of such ownership structures in aligning the interests of management and shareholders, which can lead to enhanced company performance and investor trust. Insider ownership can influence investor sentiment and company performance, but its overall effect is expected to be limited.
17 Oct
Sanara MedTech Inc. (SMTI) insiders hold a significant 31% ownership stake in the company, indicating their strong financial interest in its future performance. This level of insider ownership often aligns management's interests with those of shareholders, potentially leading to strategic decisions that favor long-term growth and stability. The article highlights the implications of this ownership structure for investor confidence and company direction. Insider ownership at this level is likely to influence strategic decisions and investor sentiment significantly.